Premier Alternatives

Kernalbio

Drug Discovery · Cambridge, MA · Founded 2016 · Privately Held (backing)

Developer of mRNA therapies designed to develop curative immunotherapies for cancers and COVID-19. Kernalbio is based in Cambridge, MA and was founded in 2016. It was valued at $111 million at its later-stage round in Jul 2022, the last priced event on record. It has raised $36.1 million across 1 recorded round; the latest was a $25 million Series A in Jul 2022.

PMV mark · valuation
$110.5M
Oct 2026
Priced at
its later-stage round
Jul 2022
Total raised
$36.1M
Last round
Later Stage VC (Series A)
Jul 2022

Kernalbio key facts

as of Oct 2026
  • Developer of mRNA therapies designed to develop curative immunotherapies for cancers and COVID-19.
  • Kernalbio is valued at approximately $110.5M as of Oct 2026, set at its later-stage round, Jul 2022; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $36.1M across 1 recorded rounds; the latest was Later Stage VC (Series A) ($25.0M) in Jul 2022.
  • Notable investors include Y Combinator, MassChallenge, Astir Ventures, Gaingels, Calm Ventures — 47 tracked in total.
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$110.5M

Valued at $110.5M at its later-stage round, Jul 2022. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Kernalbio with a free account
  • ·The complete investor list: 47 names
  • ·Watch Kernalbio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Kernalbio funding rounds

1 rounds
Jul 2022Later Stage VC (Series A)$25.0M▮
Full funding history →

Kernalbio valuation

Kernalbio was valued at $111 million at its later-stage round in Jul 2022. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Kernalbio raised?

Kernalbio has raised $36.1 million in total; 1 of its rounds is on record. The largest on record was a $25 million Series A in Jul 2022.

Kernalbio investors

47 investors are on record for Kernalbio, including Y Combinator, MassChallenge, Astir Ventures and Gaingels. By type, the record holds 6 venture capital firms. The Series A in Jul 2022 drew 20 investors.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Arsenal Medical ($124 million), Stylus Medicine ($114 million) and Nocion Therapeutics ($112 million).

About Kernalbio

Developer of mRNA therapies designed to develop curative immunotherapies for cancers and COVID-19. The company's platform decreases immunogenicity upon existing mRNA technologies and enables cell-specific therapeutic protein expression, providing clinicians with efficacious, tolerable, and affordable medicine for the global market.

Industry
Drug Discovery
Sector
Healthcare
HQ
Cambridge, MA, United States
Founded
2016
Employees
17
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.